480 related articles for article (PubMed ID: 22177289)
1. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
Di Lorenzo G; Ferro M; Buonerba C
BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
[TBL] [Abstract][Full Text] [Related]
2. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
3. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.
Patel PH; Kockler DR
Ann Pharmacother; 2008 Jan; 42(1):91-8. PubMed ID: 18094343
[TBL] [Abstract][Full Text] [Related]
4. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.
Buonerba C; Ferro M; Di Lorenzo G
Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508
[TBL] [Abstract][Full Text] [Related]
5. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.
Jarosławski S; Toumi M
BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092
[TBL] [Abstract][Full Text] [Related]
6. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
7. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
[TBL] [Abstract][Full Text] [Related]
8. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
Wei XX; Perry J; Chang E; Zhang L; Hiatt RA; Ryan CJ; Small EJ; Fong L
Clin Genitourin Cancer; 2018 Jun; 16(3):184-190.e2. PubMed ID: 29352713
[TBL] [Abstract][Full Text] [Related]
9. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
Gardner TA; Elzey BD; Hahn NM
Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
Lü C; Williams AK; Chalasani V; Martínez CH; Chin J
Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
Garcia JA; Dreicer R
Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
[TBL] [Abstract][Full Text] [Related]
12. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Sims RB
Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
[TBL] [Abstract][Full Text] [Related]
13. Sipuleucel-T: in metastatic castration-resistant prostate cancer.
Plosker GL
Drugs; 2011 Jan; 71(1):101-8. PubMed ID: 21175243
[TBL] [Abstract][Full Text] [Related]
14. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.
Cheever MA; Higano CS
Clin Cancer Res; 2011 Jun; 17(11):3520-6. PubMed ID: 21471425
[TBL] [Abstract][Full Text] [Related]
15. New treatment options for castration-resistant prostate cancer.
Simondsen K; Kolesar J
Am J Health Syst Pharm; 2013 May; 70(10):856-65. PubMed ID: 23640346
[TBL] [Abstract][Full Text] [Related]
16. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.
Sonpavde G; Di Lorenzo G; Higano CS; Kantoff PW; Madan R; Shore ND
Eur Urol; 2012 Apr; 61(4):639-47. PubMed ID: 22036643
[TBL] [Abstract][Full Text] [Related]
17. Sipuleucel-T (APC8015) for prostate cancer.
So-Rosillo R; Small EJ
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1163-7. PubMed ID: 17020451
[TBL] [Abstract][Full Text] [Related]
18. Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.
Simpson EL; Davis S; Thokala P; Breeze PR; Bryden P; Wong R
Pharmacoeconomics; 2015 Nov; 33(11):1187-94. PubMed ID: 26017401
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for advanced prostate cancer: a novel treatment option to improve survival.
Peskin SR
Manag Care; 2011 Sep; 20(9 Suppl 5):3-4, 6-11. PubMed ID: 22046617
[TBL] [Abstract][Full Text] [Related]
20. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
Wei XX; Fong L; Small EJ
Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]